These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 30898575)
1. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein. Lee ES; Jin SY; Kang BK; Jung YT J Virol Methods; 2019 Jun; 268():32-36. PubMed ID: 30898575 [TBL] [Abstract][Full Text] [Related]
2. Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy. Jin SY; Jung YT Arch Virol; 2020 May; 165(5):1089-1097. PubMed ID: 32146506 [TBL] [Abstract][Full Text] [Related]
3. A Replication-Competent Retroviral Vector Expressing the HERV-W Envelope Glycoprotein is a Potential Tool for Cancer Gene Therapy. Kang BK; Jung YT J Microbiol Biotechnol; 2024 Feb; 34(2):280-288. PubMed ID: 38247210 [TBL] [Abstract][Full Text] [Related]
4. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403 [TBL] [Abstract][Full Text] [Related]
5. MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes. Gladow M; Becker C; Blankenstein T; Uckert W J Gene Med; 2000; 2(6):409-15. PubMed ID: 11199261 [TBL] [Abstract][Full Text] [Related]
6. Characterization of R peptide of murine leukemia virus envelope glycoproteins in syncytium formation and entry. Kubo Y; Tominaga C; Yoshii H; Kamiyama H; Mitani C; Amanuma H; Yamamoto N Arch Virol; 2007; 152(12):2169-82. PubMed ID: 17851730 [TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated targeting of replication-competent retroviral vectors. Tai CK; Logg CR; Park JM; Anderson WF; Press MF; Kasahara N Hum Gene Ther; 2003 May; 14(8):789-802. PubMed ID: 12804141 [TBL] [Abstract][Full Text] [Related]
8. Production of a replicating retroviral vector expressing Reovirus fast protein for cancer gene therapy. Jeon YH; Jung YT J Virol Methods; 2022 Jan; 299():114332. PubMed ID: 34655690 [TBL] [Abstract][Full Text] [Related]
10. Replacement of the murine leukemia virus (MLV) envelope gene with a truncated HIV envelope gene in MLV generates a virus with impaired replication capacity. Nack U; Schnierle BS Virology; 2003 Oct; 315(1):209-16. PubMed ID: 14592772 [TBL] [Abstract][Full Text] [Related]
11. Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein. Sakuma T; De Ravin SS; Tonne JM; Thatava T; Ohmine S; Takeuchi Y; Malech HL; Ikeda Y Hum Gene Ther; 2010 Dec; 21(12):1665-73. PubMed ID: 20507233 [TBL] [Abstract][Full Text] [Related]
12. Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope. Mirow M; Schwarze LI; Fehse B; Riecken K Viruses; 2021 Jul; 13(8):. PubMed ID: 34452336 [TBL] [Abstract][Full Text] [Related]
13. Mutational library analysis of selected amino acids in the receptor binding domain of envelope of Akv murine leukemia virus by conditionally replication competent bicistronic vectors. Bahrami S; Jespersen T; Pedersen FS; Duch M Gene; 2003 Oct; 315():51-61. PubMed ID: 14557064 [TBL] [Abstract][Full Text] [Related]
14. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. von Kalle C; Kiem HP; Goehle S; Darovsky B; Heimfeld S; Torok-Storb B; Storb R; Schuening FG Blood; 1994 Nov; 84(9):2890-7. PubMed ID: 7524756 [TBL] [Abstract][Full Text] [Related]
15. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095 [TBL] [Abstract][Full Text] [Related]
16. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. Mühlebach MD; Schmitt I; Steidl S; Stitz J; Schweizer M; Blankenstein T; Cichutek K; Uckert W J Mol Med (Berl); 2003 Dec; 81(12):801-10. PubMed ID: 14576928 [TBL] [Abstract][Full Text] [Related]
17. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290 [TBL] [Abstract][Full Text] [Related]
18. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671 [TBL] [Abstract][Full Text] [Related]
19. Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU. Ott D; Rein A J Virol; 1992 Aug; 66(8):4632-8. PubMed ID: 1321266 [TBL] [Abstract][Full Text] [Related]
20. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Russell DW; Berger MS; Miller AD Hum Gene Ther; 1995 May; 6(5):635-41. PubMed ID: 7578400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]